

STEMLINE THERAPEUTICS INC  
Form 8-K  
August 14, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **August 14, 2014**

**Stemline Therapeutics, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-35619**  
(Commission File Number)

**45-0522567**  
(IRS Employer Identification  
No.)

**750 Lexington Avenue**  
**Eleventh Floor**  
**New York, New York 10022**

Edgar Filing: STEMLINE THERAPEUTICS INC - Form 8-K

(Address of Principal Executive Offices)

**(646) 502-2311**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act.
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
  - Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
-

**Item 2.02. Results of Operations and Financial Condition.**

On August 14, 2014, Stemline Therapeutics, Inc. ( Stemline or the Company ) issued a press release to provide a corporate update and to announce its financial results for the second quarter ended June 30, 2014. A copy of such press release is being furnished as Exhibit 99.1 to this report.

**Item 9.01. Financial Statements And Exhibits.**

(d) Exhibits.

The following exhibit is furnished herewith:

99.1 Press release issued by Stemline Therapeutics, Inc., dated August 14, 2014.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Stemline Therapeutics, Inc.**  
(Registrant)

Date: August 14, 2014

By: */s/ Kenneth Hoberman*  
Kenneth Hoberman  
Chief Operating Officer

**INDEX TO EXHIBITS**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press release issued by Stemline Therapeutics, Inc., dated August 14, 2014.